The Chinese D2C microbiome testing market is growing rapidly. The estimated market size in 2023 was ~USD50-80 million, and with a projected CAGR of 20-30%, it has an expected 2030 Market Size of USD200-300 million. Main growth drivers include increased consumer interest in gut health, probiotics and personalized nutrition, as well as advances in e-commerce & digital health platforms such as Tmall and WeChat.

The Thalys microbiome testing service powered by the GA-map® Dysbiosis Test will provide consumers in China with a fast and affordable test. Thalys has developed a D2C mobile software where customers can easily subscribe, pay and view report results on their mobile phones. The results will offer insights into the beneficial and potentially harmful microbes present in the gut, along with potential health- and wellness implications. Test results will include personalized probiotics recommendations as well as weight management & metabolic health insights.

The upcoming launch of the GA-map® Dysbiosis Test to the Chinese Consumer Health market marks the completion of the first stage of the Thalys and GA collaboration. Moving forward, the Thalys Group will further develop and distribute tests based on GA's GA-map® Technology in China.

President and Board Member of Thalys Group, Zheng Wang (James) comments:
"We are incredibly proud to reach this pivotal milestone with our esteemed partner, Genetic Analysis, as we are launching the GA-map® Dysbiosis Test tailored for China's dynamic Consumer Health market. This achievement underscores the power of strategic collaboration, combining GA's globally recognized microbiome technology with Thalys' deep-rooted expertise in China's healthcare ecosystem. This launch is not just a testament to our shared vision but also a critical step in Thalys' commitment to advancing precision diagnostics and personalized health solutions. The GA-map® platform's robustness, paired with our Thalys Medical Lab capabilities, empowers Chinese consumers with actionable insights into gut health-bridging innovation with accessibility.

Together, we aim to set new industry benchmarks, driving value for consumers, clinicians, and stakeholders alike. This collaboration exemplifies Thalys' mission to be the most innovative and trusted partner in transforming healthcare - one breakthrough at a time."

CEO Ronny Hermansen comments:
"We are thrilled to have completed the development enabling our partner Thalys to launch the GA-map® Dysbiosis Test in China. This endeavour, constituting significant efforts including clinical studies and software development, enabling Thalys to launch a microbiome testing service tailormade for the huge Chinese Consumer Health Market. The Chinese market is characterized by high growth and a significant interest in microbiome related health issues and this market might in the future overtake the US as the most important market in the world for microbiome related diagnostics. The consumer health market needs reliable, user-friendly microbiome tests that offer actionable insights into gut health, and the GA-map® Dysbiosis Test offers exactly this." 

Within the framework of the cooperation, GA will supply reagent kits to Thalys. Thalys has invested in the clinical study activities associated with the project and developing front-end consumer software solutions, whereas GA has contributed its proprietary software and algorithm development from internal resources. The agreement set out for the cooperation is structured as an ongoing partnership without predefined order volumes or minimum delivery commitments, but revenues will be generated for GA based on the number of tests sold. GA is not obliged to make any additional financial investments as part of the collaboration.

References:
China Direct-to-Consumer Genetic Testing Market Report (2023) - iResearch.
China Digital Health Consumer Trends (2024) - MobTech.
Global Microbiome Testing Industry Report (2023) - Grand View Research.
China Probiotics Industry Development Report (2024) - China Nutrition Society.

For more information on Genetic Analysis, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com

For more information on Thalys, please contact:
Zheng Wang (James), President
E-mail: wangzheng@thalys.net.cn

This disclosure contains information that Genetic Analysis AS is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, at the time indicated by Genetic Analysis AS news distributor upon publication of this press release.

About Thalys Medical Technology Group Corporation
Thalys Medical Technology Group Corporation (so called Thalys Group) is an enterprise with long history and solid experiences in the integrated operation and services of hospital IVD laboratories. Thalys Group was established in 1998 at Tianjin city and became a public company (Stock Code: 603716.SH) listed in the main stock board at Shanghai Stock Exchange (SSE) in 2016. Thalys Group is a leading integrated solution provider for medical supply chain management with a greater focus on IVD technology, solution, and products.

Thalys Group 's main business scope encompasses multiple segments within the healthcare industry. The company is a leading provider of integrated IVD lab solutions, offering reagent and kit supply, lab automation platform placement, LIS and IoT solution deployment, and full-process supply chain management. In addition, Thalys is a renowned provider of hospital SPD integrated solutions and operations for medical consumables, ensuring seamless and efficient management of medical resources. In addition to its core business, Thalys Group is involved in the manufacture and distribution of IVD products, offering a comprehensive range of diagnostic products and innovations that cater to the evolving needs of the healthcare market.

Thalys Group is aspired to be the most innovative and trusted partner for China's healthcare sector by building upon the talents, expertise, innovation and intelligence and to integrate technology, products, distribution and services into the solutions that are beneficial to patients, medical practitioners, hospitals and partners.''

Thalys Medical Group nationwide distribution & service network covers more than 23 provinces & 200 cities, supplying to around 2,000 hospitals and about 200 hospital IVD labs, and partnering with 5,000 suppliers and manufacturers in China.  Thalys Medical Group is headquartered both in Wuhan and Shanghai, with more than 50 subsidiaries and more than 1,400 FTEs by the end of 2023. Thalys Group also commits to engage in Life Science & Diagnostic technology by investing into several pioneering and innovative start-ups in single cell analysis and mRNA transcriptomic diagnostics.

More info at Thalys Group Office website: www.thalys.net.cn

About Thalys MedLab/TML
Shanghai Thalys Medical Laboratory Co., Ltd (Thalys MedLab/TML) is an independent third-party medical testing laboratory under Thalys Medical Group. It is a medical testing public service platform accredited by the Science and Technology Commission of Baoshan District, Shanghai High-tech Enterprise. TML is a leading provider of medical testing services, committed to delivering accurate and high-end solutions for a range of clients, including medical institutions, associations and other customers. Our services are available through various types of medical testing laboratories, such as medical institutions, medical consortiums and medical groups. We are proud to offer a comprehensive range of medical testing laboratories, catering to the needs of various medical institutions, consortia and groups.

TML's services includes 'precision medicine testing co-construction', 'one-stop medical testing centre characteristics of the testing and diagnostic services', and 'Internet + hospital testing centre characteristics'. Transformation services for scientific research projects of institutions, central laboratory testing services of pharmaceutical companies, drug companion diagnostics and LDT project transformation, and regional public service testing platform services.

TML is actively involved in innovation and further development of precision medicine testing and diagnostics in China through cooperation with some of the best research pioneers in the world with this field. Examples of this includes  Nanopore, a sequencing technology company based in Oxford (Nanopore Gridon); NanoString, a company specialising in transcriptomics technology in mRNA transcriptomics detection system as well as liquid-phase magnetic levitation microfluidic single-cell histological analysis system (LeviCell™); COPAN, a globally renowned clinical microbiology digital automated diagnostic company ( Copan WASPLab®) in addition to the current partnership with  Genetic-Analysis AS, a European gut microbiology research and innovation company in digital liquid-phase ultra-multiplexed gut microbiomics (GA-map® with Luminex xMAP® system). The laboratory has established a dual-faceted development strategy, encompassing scientific research services and clinical medical translation and application.

About Genetic Analysis 
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in sales, operations, bioinformatics, molecular biology, and bioengineering.

For more general information: www.genetic-analysis.com

Interested in reading more about GA's products? Please visit ga-map.com

Stay updated on GA and sign up for more investor-related information:

https://www.genetic-analysis.com/subscriptions/